Full Press Release Details
Mr. Cross serves as the Chief Financial Officer of Senti Bio, where he oversees the company’s financial strategy, operations, and investor relations. His leadership plays a key role in supporting the company’s ongoing growth and clinical development. Prior to joining Senti, Mr. Cross was the Chief Financial Officer at Sonnet BioTherapeutics, where he managed the financial operations of the company, oversaw investor relations and directed the capital markets and investment banking initiatives.
As a complement to his corporate experience, Mr. Cross enjoyed a 20-year career on Wall Street, where he served as a managing director in the healthcare investment banking practice at Chardan, in addition to working as a professional investor on globally diversified healthcare portfolios at several funds, including SAC Capital, Citadel, and Balyasny Asset Management. Mr. Cross launched his career in finance covering biotechnology for the equity research divisions at Hambrecht & Quist and Goldman Sachs. He earned a Master of Public Health from the Yale University School of Medicine and a Bachelor of Science in psychology from Washington & Lee University.